Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office buildings previously owned by Horizon Therapeutics, then Amgen Inc., at ...

BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on January 14.Invest with Confidence: ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), boosting the price ...

NDAQ:HOTH) Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

The global cancer therapeutics market is on an exponential growth trajectory, driven by advancements in treatment methodologies, increased investment in cancer research, and the rising global burden ...

The Global Ophthalmic Disease Therapeutics market showcased growth ... healthcare infrastructure are anticipated to propel market expansion. The rising incidence of lifestyle-related eye diseases ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Amicus Therapeutics reports 2024 revenue of $528M, a 32% increase, with positive 2025 growth projections for key therapies. 2024 total revenue reached $528.5 million, marking a significant year ...